实时荧光定量PCR监测治疗前后BCR-ABL水平的变化  

Real-time fluorescent quantitative PCR monitoring BCR-ABL level changes before and after the treatment

作　　者：肖恒[1] 任彦斌[2] 周淑杰[1] 秦志梅[1] 许玲[1] 李守霞[1] XIAO Heng;REN Yan-bin;ZHOU Shu-jie;QIN Zhi-mei;XU Ling;LI Shou-xia(Handan Central Hospital Clinical Laboratory;Handan Central Hospital Functional Department,Handan,056008,China)

机构地区：[1]邯郸市中心医院检验科 [2]邯郸市中心医院功能科,河北邯郸056008

出　　处：《中国优生与遗传杂志》2018年第8期13-14,共2页Chinese Journal of Birth Health & Heredity

摘　　要：目的探讨实时荧光定量PCR(Quantitative Real-time PCR,RQ-PCR)方法在监测慢性粒细胞白血病(chronic myeloid leukemia,CML)患者治疗效果和预后判断的应用价值。方法应用实时荧光定量PCR方法分别检测CML患者采用异基因造血干细胞移植或伊马替尼治疗前、治疗3个月、治疗6个月、治疗1年时BCR-ABL融合基因的表达水平。结果治疗前,CML患者的BCR-ABL水平分布在164%~469%,造血干细胞移植组的患者的BCR-ABL水平降至0.1%~0.2%,伊马替尼组患者随着治疗BCR-ABL水平逐渐下降,在治疗一年后降至0.1%~0.3%。治疗前后患者的BCR-ABL水平差异有统计学意义(P<0.05),造血干细胞移植组与伊马替尼组患者的BCR-ABL水平差异不显著(P>0.05)。结论使用RQ-PCR方法监测BCR-ABL水平可以作为CML患者评价治疗效果和判断预后的指标。Objective：To study the application value of Quantitative Real-time PCR（RQ-PCR）method in monitoring the treatment effect and prognostic in patients of chronic myeloid leukemia（CML）. Methods：Applied RQ-PCR to detect the expression level of BCR-ABL fusion gene in the CML patients treated by allogeneic hematopoietic stem cell transplantation or imatinib therapy,the detection time included untreated,treatment for 3 months,6 months and 1 year. Results：Before the treatment,the level of BCR-ABL fusion gene in patients with CML distributed between 164%～469%,and the level of BCRABL fusion gene in the group of patients with hematopoietic stem cell transplantation was between 0.1%～0.2%,the level of BCRABL fusion gene in the group of patients with treatment of imatinib BCR-ABL was gradually declining,and it can declined to 0.1%～0.3% in one year after treatment. The difference of the level of BCR-ABL fusion gene in patients before and after treatment was statistically significant（P〈0.05）. The difference of the level of BCR-ABL fusion gene between the group of patients with hematopoietic stem cell transplantation and imatinib therapy was not significant（P〉0.05）. Conclusion：Using the method of RQ-PCR to monitor the level of BCR-ABL fusion gene can be used as the index for evaluating the effect of the treatment and prognosis in CML patients.

关 键 词：慢性粒细胞白血病 BCR-ABL 实时荧光定量PCR 

分 类 号：R733.72[医药卫生—肿瘤]